UBS/CALL/ROCHE GS/400.004/0.025/19.12.25 Stock

Warrant

CROGRU

CH1147771211

Real-time Bid/Ask 05:14:21 2024-06-03 EDT
0.031 CHF / 0.05 CHF +2.50% Intraday chart for UBS/CALL/ROCHE GS/400.004/0.025/19.12.25
1 month+11.11%
3 months+33.33%

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
CROGRU
ISINCH1147771211
Date issued 2021-12-15
Strike 400 CHF
Maturity 2025-12-19 (565 Days)
Parity 40 : 1
Emission price 0.96 CHF
Emission volume N/A
Settlement physical
Currency CHF

Technical Indicators

Highest since issue 1.23 CHF
Lowest since issue 0.02 CHF
Spread 0.019 CHF
Spread %38.00%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus
  1. Stock Market
  2. Warrants
  3. CROGRU Warrant